Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 4/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.53 |
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29824884 | 0.85 | F2 (0.55) | ACEF2OPRM1OPRD1APLNR | |
| SCHEMBL31433252 | 0.85 | GRB2 (0.50) | DPP3ACEF2 | |
| SCHEMBL31717948 | 0.85 | OPRM1 (0.56) | DPP3OPRM1OPRD1SLC6A2 | |
| SCHEMBL30543190 | 0.85 | F2 (0.61) | ACEF2OPRM1OPRD1APLNR | |
| SCHEMBL31433238 | 0.84 | GRB2 (0.51) | DPP3ACEF2OPRM1 | |
| SCHEMBL30512720 | 0.84 | APLNR (0.53) | F2OPRM1OPRD1APLNR | |
| SCHEMBL31324068 | 0.83 | DPP3 (0.52) | DPP3F2SLC6A2 | |
| SCHEMBL31511422 | 0.83 | APLNR (0.55) | DPP3ACEF2OPRM1OPRD1 | |
| SCHEMBL31505799 | 0.83 | F2 (0.58) | ACEF2OPRM1OPRD1SLC6A2 | |
| SCHEMBL31362693 | 0.82 | OPRM1 (0.55) | ACEF2OPRM1OPRD1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024211447-A1 | TP508 MRNAS | CHRYSALIS BIOTHERAPEUTICS (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20230165943-A1 | TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION | CHRYSALIS BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-4132948-A1 | TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION | Chrysalis Biotherapeutics (US) | 2023-02-15 | — | — | EP | disclosed |